🇺🇸 FDA
Pipeline program

PIVEKIMAB SUNIRINE

Phase 2 small_molecule active

Quick answer

PIVEKIMAB SUNIRINE for Acute Myeloid Leukemia and other blood cancers is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Acute Myeloid Leukemia and other blood cancers
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials